Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.
When Susan Wright learned that she had a type of fatal, rapidly growing brain cancer at age 46, her doctors at the University of Florida told her she wouldn't live more than 18 months.
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer.
Glioblastoma multiforme is among the most aggressive and difficult cancers to treat. Now, researchers at Penn State University have shown that a lipid-based nanoparticle, designed to bind to a specific receptor found on malignant brain cells but not healthy ones, improves the potency of a common anticancer drug and slows significantly the growth of glioblastoma in mice.
A new method for targeting malignant brain tumors through inducing the cancerous cells to "commit suicide" has been developed by a team of researchers headed by a Hebrew University of Jerusalem professor of biochemistry.
It is estimated that 174,470 new cases of lung cancer will be diagnosed in the United States in 2006. Lung cancer is the major cause of cancer-related mortality in both men and women, with an estimated 162,460 deaths expected to occur in 2006.
Low-density lipoprotein, better known as LDL, is one of the chief villains involved in the development of coronary artery disease.
Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation, and may hold the key to treating these deadly cancers.
Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.
Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma
Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.
Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder.
In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.
In a study published in the March 15 issue of The Journal of Immunology, researchers at Board of Governors' Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have developed a way to overcome immune privilege in the brain to eradicate potentially deadly brain tumors such as glioblastoma multiforme and other types of brain infections.
One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.
A research team at UT Southwestern Medical Center has discovered a cell-signaling mechanism instrumental in the most common brain cancer in adults.
Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM).
Researchers at UCLA's Jonsson Cancer have identified key characteristics in certain deadly brain tumors that make them 51 times more likely to respond to a specific class of drugs than tumors in which the molecular signature is absent.
Does a combination of radiation therapy and the inhibition of integrins (key molecules in angiogenesis) improve the chance of cure in cancer?
Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.